IP Library › Granted Patent US 8,901,124
Granted Patent B2
US 8,901,124 · App. 13/738,098 · Granted Dec 2, 2014

Pyridazine amide compounds useful as SYK inhibitors

Inventors: Johannes Cornelius Hermann (Jersey City, NJ); Joshua Kennedy-Smith (New York, NY); Matthew C. Lucas (Lexington, MA); Fernando Padilla (Verona, NJ); Michael Soth (Glen Rock, NJ)
Assignee: Hoffmann-La Roche Inc.
C07D471/04A61K45/06A61K31/50C07D401/14C07D403/12A61K31/501C07D405/14C07D237/24C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,901,124
App. No.
13/738,098
Granted
Dec 2, 2014
Kind
B2
Abstract

The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Claims (67)

1. A compound of Formula I:

wherein:

A is cycloalkyl or heterocycloalkyl;

each X is independently amino, C(═O)NHR, C(═O)R, C(═O)OR, OR, NHC(═O)R, CH 2 NHR, lower alkyl, hydroxy lower alkyl, or hydroxy lower alkyl amino;

each R is independently H, or R′;

each R′ is independently lower alkyl, heterocycloalkyl, phenyl, heteroaryl, or heteroaryl lower alkyl, optionally substituted with one or more R″;

each R″ is independently hydroxy, lower alkyl amido, carboxy, oxo, lower alkoxy, lower alkyl amino, or lower dialkyl amino;

m is 0, 1, or 2;

B is phenyl or mono- or bicyclic heteroaryl;

each Y is independently halo, lower alkyl, lower alkoxy, lower haloalkyl, lower hydroxyalkyl, heteroaryl, lower alkyl sulfonyl, cycloalkyl, or heterocycloalkyl; and

n is 0, 1, or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein B is pyridyl.

3. The compound of claim 2 , wherein A is cyclohexyl or tetrahydropyranyl.

4. The compound of claim 3 , wherein m is 1.

5. The compound of claim 4 , wherein X is amino.

6. The compound of claim 5 , wherein n is 1.

7. The compound of claim 6 , wherein Y is lower alkyl, cycloalkyl, heteroaryl, or lower alkyl sulfonyl.

8. The compound of claim 7 , wherein Y is lower alkyl.

9. The compound of claim 5 , wherein n is 2.

10. The compound of claim 9 , wherein one Y is lower alkyl and the other is halo or lower alkyl.

11. The compound of claim 1 , wherein B is pyrrolo[2,3-b]pyridyl or pyrazolyl.

12. A pharmaceutical composition comprising the compound of claim 1 admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

13. A compound selected from the group consisting of:

6-(cis-2-Amino-cyclohexylamino)-4-(6-methyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-(cis-2-Amino-cyclohexylamino)-4-(6-ethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((3R,4R)-3-Amino-tetrahydro-pyran-4-ylamino)-4-(6-methyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1S,2R)-2-Amino-cyclohexylamino)-4-(6-[1,2,3]triazol-1-yl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-(cis-2-Amino-cyclohexylamino)-4-(5-methanesulfonyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-p-tolylamino-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-isopropyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((3R,4R)-3-Amino-tetrahydro-pyran-4-ylamino)-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(1-methyl-1H-pyrazol-3-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-methyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-6-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-cyclopropyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(5-fluoro-6-methyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1S,2R)-2-Amino-cyclohexylamino)-4-(6-ethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(5-chloro-6-methyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(5,6-dimethoxy-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(4,6-dimethylpyridin-2-ylamino)pyridazine-3-carboxamide 2,2,2-trifluoroacetate;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6-tert-butylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-(cyclohexylamino)-4-(6-cyclopropylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6-cyclobutylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(1-methyl-1H-benzo[d]imidazol-4-ylamino)pyridazine-3-carboxamide;

4-(6-(2H-1,2,3-triazol-2-yl)pyridin-2-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6,7-dihydro-5H-cyclopenta[b]pyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-isopropyl-5-methyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6-propylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((3R,4R)-3-Amino-tetrahydro-pyran-4-ylamino)-4-(6-isopropyl-5-methyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(3,5-dimethylphenylamino)pyridazine-3-carboxamide;

6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(6-tert-butylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6-ethoxypyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(5-methoxy-6-propylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6-isopropyl-5-methoxypyridin-2-ylamino)pyridazine-3-carboxamide;

4-(6-(1H-pyrazol-1-yl)pyridin-2-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)pyridazine-3-carboxamide;

6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(6-isopropyl-5-methoxypyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6-isopropyl-4-methylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6-(2-cyanopropan-2-yl)pyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(6-(2-hydroxypropan-2-yl)pyridin-2-ylamino)pyridazine-3-carboxamide;

6-((1R,2S)-2-aminocyclohexylamino)-4-(4-methyl-6-propylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(4-methyl-6-propylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(5-methoxy-6-propylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(5-fluoro-6-isopropylpyridin-2-ylamino)pyridazine-3-carboxamide;

6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(5-isopropyl-6-methoxypyridin-2-ylamino)pyridazine-3-carboxamide; and

6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(6-isopropoxypyridin-2-ylamino)pyridazine-3-carboxamide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2013
From: HERMANN, JOHANNES CORNELIUS; KENNEDY-SMITH, JOSHUA; LUCAS, MATTHEW C.; PADILLA, FERNANDO; SOTH, MICHAEL
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 029628/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2013
From: HERMANN, JOHANNES CORNELIUS; LUCAS, MATTHEW C.; PADILLA, FERNANDO; SOTH, MICHAEL
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 029628/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2013
From: KENNEDY-SMITH, JOSHUA
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 029628/0501 →
Continuity (3)
Provisional Application 61584859 · Jan 10, 2012
Provisional Application 61696855 · Sep 5, 2012
Related Publication 20130178478A1 · Jul 11, 2013